Houston, Texas–(Newsfile Corp. – September 9, 2020) – With the pandemic still showing no signs of abating, demand for diagnostic testing has only increased. Unfortunately, the nation is still running into severe diagnostic test shortages, which could hamper the nation’s response to the pandemic.

In fact, according to Barron’s, “The sudden worldwide demand for accurate, high-quality testing is unlike anything the industry has experienced before. Manufacturers are being asked to quickly scale up from millions of tests per month to millions per week, and the materials are not always available to meet the immediate need.”

On top of that, many schools and universities are planning to regularly test students and staff on campuses across the U.S. to help keep everyone safe.

That increases the need for even more diagnostic tests, too.

In addition, while the Trump Administration hopes to have 20 million rapid and point-of-care tests available by the end of September 2020, reports Politico, some health experts say the U.S. needs as many as 25 million tests by October just to ensure safe operation of schools, businesses, states, and health facilities.

The situation has grown so dire Congress could soon consider legislation to ensure there are enough tests to go around. In fact, according to former U.S. FDA Commissioner Scott Gottlieb, and Dr. Mark McClellan, director of the Duke-Margolis Center for Health Policy, “Washington could contract with commercial labs and point-of-care test manufacturers to develop and maintain diagnostic capacity for a crisis. Think of it as part of the national stockpile. Under such contracts, companies would build more labs and sprinkle them throughout the country so capacity could be available wherever it’s needed.”

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) Could Be a Big Part of the Solution

XPhyto and its exclusive diagnostic partner, 3a-Diagnostics GmbH, are developing a rapid, disposable, point-of-care lateral flow screening test to detect COVID-19 viral RNA from patient saliva samples and nasal and throat swabs .

On July 6, 2020, the Company announced successful validation of its working prototype to concurrently detect the COVID-19 virus and viruses in the broader coronavirus family (including SARS-CoV and MERS-CoV). On August 10, 2020, the Company announced commercial milestones targeting European regulatory approval in Q1 2021.

3a has taken possession of COVID-19 RNA isolated from live viable virus for its second round of proof of concept prototype testing. This evaluation process is currently underway and results are expected within 30 days. Pending successful evaluation results the Company will proceed to advanced prototype production and usability testing scheduled for Q4 2020. Test development and optimization continues to proceed on an expedited basis at 3a’s research lab and in collaboration with third party contractors and academic partners in Germany.

“In general, the scientific understanding of the COVID-19 virus and an active infection is rapidly evolving. It’s a dynamic situation but XPhyto is bolstered by the emerging scientific literature that supports the use of saliva tests over nasopharyngeal swabs and molecular (RNA) tests over other forms of detection, which may be susceptible to false negatives,” said Hugh Rogers, CEO of XPhyto.

XPhyto and 3a are developing rapid screening tests for COVID-19 and other high-risk pandemic threats, including H1N1 (swine flu) and H5N1 (avian flu), with a specific focus on early pre-symptomatic and asymptomatic stages of infection. H1N1 and H5N1 development programs are currently funded through grants from the German Federal Ministry of Education and Research. The Company’s screening tests include enhanced RNA-probe lateral flow assay tests as well as novel biosensors delivered via XPhyto’s oral dissolvable drug delivery platform. The product pipeline is comprised exclusively of next generation rapid, low-cost, easy-to-use, saliva-based screening tools designed to be self-administered, making them ideal for decentralized population-scale screening.

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 pandemic.

For more information, visit the company’s website at https://www.xphyto.com

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

For making specific investment decisions, readers should seek their own advice. Winning Media is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement between Winning Media and XPhyto Therapeutics Corp., Winning Media has been paid two thousand dollars for advertising and marketing services for XPhyto Therapeutics Corp. We own ZERO shares of XPhyto Therapeutics Corp. Please click here for full disclaimer.

Contact Information:
2818047972
[email protected]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/63475